Biohaven Ltd. (BHVN)
| Market Cap | 2.07B +32.9% |
| Revenue (ttm) | n/a |
| Net Income | -586.84M |
| EPS | -4.48 |
| Shares Out | 151.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,308,721 |
| Open | 13.95 |
| Previous Close | 13.85 |
| Day's Range | 13.56 - 14.00 |
| 52-Week Range | 7.48 - 18.57 |
| Beta | 3.16 |
| Analysts | Buy |
| Price Target | 23.07 (+68.64%) |
| Earnings Date | Aug 10, 2026 |
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price target is $23.07, which is an increase of 68.64% from the latest price.
News
Biohaven price target raised to $19 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Biohaven (BHVN) to $19 from $18 and keeps an Overweight rating on the shares. Key pipeline programs remain on track, says the…
Biohaven price target raised to $23 from $22 at RBC Capital
RBC Capital raised the firm’s price target on Biohaven (BHVN) to $23 from $22 and keeps an Outperform rating on the shares. The firm cites the company’s better-than-expected Q2 results,…
Biohaven reports Q2 EPS (78c), consensus (61c)
Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2026, totaled approximately $270.5M. Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven (BHVN), comment...
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical...
Biohaven Quarterly report: Q2 2026
Biohaven has published its Q2 2026 quarterly earnings report on August 10, 2026.
Biohaven Earnings release: Q2 2026
Biohaven released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug development NEW HAVEN, Conn., Aug. 6, ...
Biohaven and Yale University awarded $4M in trade secret verdict
Biohaven (BHVN) and Yale University announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in the trade secret…
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.
Biohaven reports new data on BHV-1530
Biohaven (BHVN) announced that new data on BHV-1530, its FGFR3-directed antibody-drug conjugate, or ADC, using a novel topoisomerase I, or TopoIx, payload, will be presented at the European Society fo...
Biohaven enters into clinical supply agreement with Regeneron
Biohaven (BHVN) has entered into a clinical supply agreement with Regeneron Pharmaceuticals (REGN) to evaluate the combination of BHV-1530 and cemiplimab, or Libtayo, in patients with solid tumors bas...
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show ...
Biohaven’s Bruce Car retires as chief scientific officer
Biohaven (BHVN) announced scientific leadership role transitions designed to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President ...
Biohaven Announces Scientific Leadership Transitions
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.
Biohaven announces completion of enrollment in RISE3 trial
Biohaven (BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled studies evaluating its selective Kv7.2/7.3 channel activator, opakalim...
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy...
Biohaven enrolls first patient in Phase 3 trial of BHV-1300 for Graves’ disease
Biohaven (BHVN) announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves’ disease. BHV-1300 is the first MoDE extracellular protein degrader, a novel small…
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the root ...
Biohaven downgraded to Underperform from Neutral at BofA
BofA downgraded Biohaven (BHVN) to Underperform from Neutral with a price target of $11, down from $12, to reflect a “bearish view” on the risk-reward into the next major near-term…
Biohaven price target raised to $20 from $15 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Biohaven (BHVN) to $20 from $15 and keeps a Buy rating on the shares. The firm says the company’s troriluzole in spinocerebellar…
Biohaven initiates first-in-human dosing for BHV-8100
Biohaven (BHVN) announced the initiation of first-in-human dosing for BHV-8100, its oral, brain-penetrant pyruvate kinase M2 isoform modulator. Dr. Bruce Car, Chief Scientific Officer of Biohaven, sta...
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders Fir...
Biohaven’s candidates in Graves’ Disease and IgA nephropathy shows efficacy
Biohaven (BHVN) reported “compelling” results regarding its proprietary extracellular MoDE – BHV-1300 – and TRAP – BHV-1400 – degrader platform. Key highlights from the Phase 1b Graves’ Disease patien...